Stock investors of Central Pharmaceuticals have been unsettled after the auditor of the listed drug maker issued an adverse opinion, warning of significant uncertainty over the company’s ability to ...
Fusen Pharmaceutical Co., Ltd. ( (HK:1652) ) has provided an update.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback